EVARREST® Fibrin Sealant Patch demonstrated superior hemostatic efficacy on the 1st attempt¹²

**Soft-tissue hemorrhage**

<table>
<thead>
<tr>
<th>% of patients achieving hemostasis</th>
<th>EVARREST</th>
<th>SURGICEL® Original Absorbable Hemostat</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td></td>
<td>Δ 46.7% P&lt;0.0001</td>
</tr>
<tr>
<td>53.3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Per protocol efficacy measured at n=87, safety assessed at n=148.

**Normal and abnormal liver resection hemorrhage**

<table>
<thead>
<tr>
<th>% of patients achieving hemostasis</th>
<th>EVARREST</th>
<th>Conventional adjunctive methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>94.3%</td>
<td></td>
<td>28.6%</td>
</tr>
<tr>
<td>25.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Per protocol efficacy measured at n=77, safety assessed at n=104.

The PP results are similar to the intention-to-treat results from the randomized controlled clinical trials. The PP results represent patients treated with no major violations to the clinical study protocol.

**EVARREST was studied in the following oncologic open surgical procedures**²⁴:

- Lung resection
- Pancreaticoduodenectomy
- Prostatectomy
- Nephrectomy
- Hysterectomy
- Hepatectomy

**Disclaimer:** The primary endpoints of these studies did not include an evaluation of the safety and efficacy of EVARREST in these specific procedures.

**Combining thousands of woven fibers and active human biologics**¹⁰

**EVARREST is ready to use, right out of the box**⁵

---

**ONCOLOGY**

**EVARREST®**

EVARREST® Fibrin Sealant Patch demonstrated superior hemostatic efficacy on the 1st attempt¹²

**Soft-tissue hemorrhage**

<table>
<thead>
<tr>
<th>% of patients achieving hemostasis</th>
<th>EVARREST</th>
<th>SURGICEL® Original Absorbable Hemostat</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td></td>
<td>Δ 46.7% P&lt;0.0001</td>
</tr>
<tr>
<td>53.3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Per protocol efficacy measured at n=87, safety assessed at n=148.

**Normal and abnormal liver resection hemorrhage**

<table>
<thead>
<tr>
<th>% of patients achieving hemostasis</th>
<th>EVARREST</th>
<th>Conventional adjunctive methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>94.3%</td>
<td></td>
<td>28.6%</td>
</tr>
<tr>
<td>25.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Per protocol efficacy measured at n=77, safety assessed at n=104.

The PP results are similar to the intention-to-treat results from the randomized controlled clinical trials. The PP results represent patients treated with no major violations to the clinical study protocol.

**EVARREST was studied in the following oncologic open surgical procedures**²⁴:

- Lung resection
- Pancreaticoduodenectomy
- Prostatectomy
- Nephrectomy
- Hysterectomy
- Hepatectomy

**Disclaimer:** The primary endpoints of these studies did not include an evaluation of the safety and efficacy of EVARREST in these specific procedures.

**Combining thousands of woven fibers and active human biologics**¹⁰

**EVARREST is ready to use, right out of the box**⁵
Indications and Usage

EVARREST® is a fibrin sealant patch indicated for use with manual compression as an adjunct to hemostasis in adult patients undergoing surgery, when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical.

Limitations for Use

• Cannot be used in place of sutures or other forms of mechanical ligation in the treatment of major arterial or venous bleeding.
• Not for use in children under one month of age.
• Laparoscopic and other minimally invasive surgeries where manual compression would be difficult to achieve.

Important Safety Information

• For topical use only. Apply immediate manual compression over the entire surface of the patch and maintain contact pressure for 3 minutes to control the bleeding.
• Do not apply intravenously. This can result in life threatening thromboembolic events.
• Do not use to treat bleeding from large defects in arteries or veins where the injured vascular wall requires conventional surgical repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST® to blood flow and/or pressure during absorption of the product. Thrombosis can occur if absorbed systemically.
• Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products. EVARREST® can cause hypersensitivity reactions including anaphylaxis.
• Avoid application to contaminated areas of the body or in the presence of active infection. Infection can occur.
• EVARREST contains oxidized regenerated cellulose which adheres to bleeding surfaces. Inadvertent adhesions can occur.
• Avoid use in, around, or in proximity to, foramina in bone or areas of bony confines where swelling may cause compression.
• Use the least number of patches required to cover the entire bleeding area. Portions of excess patch material can become dislodged and migrate to other areas of the body.
• Do not use more than eight 2x4 inch (5.1 x 10.2 cm) or more than four 4x4 inch (10.2 x 10.2 cm) patches.
• Use in patients who have been previously exposed to EVARREST® has not been studied.
• Do not use more than eight 2x4 inch (5.1 x 10.2 cm) or more than four 4x4 inch (10.2 x 10.2 cm) patches.
• Avoid application to contaminated areas of the body or in the presence of active infection. Infection can occur.
• EVARREST contains oxidized regenerated cellulose which adheres to bleeding surfaces. Inadvertent adhesions can occur.
• Avoid use in, around, or in proximity to, foramina in bone or areas of bony confines where swelling may cause compression.
• Use the least number of patches required to cover the entire bleeding area. Portions of excess patch material can become dislodged and migrate to other areas of the body.
• Do not use more than eight 2x4 inch (5.1 x 10.2 cm) or more than four 4x4 inch (10.2 x 10.2 cm) patches.
• Use in patients who have been previously exposed to EVARREST® has not been studied.

Please see package insert for EVARREST® Full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at 1-877-384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.